留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肠道菌群在自身免疫性疾病治疗中的前景

赵丽丹 孟夏 徐浩杰 张奉春

赵丽丹, 孟夏, 徐浩杰, 张奉春. 肠道菌群在自身免疫性疾病治疗中的前景[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0245
引用本文: 赵丽丹, 孟夏, 徐浩杰, 张奉春. 肠道菌群在自身免疫性疾病治疗中的前景[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0245
ZHAO Lidan, MENG Xia, XU Haojie, ZHANG Fengchun. Prospect of Gut Microbiota Based Intervention in Autoimmune Disease Control[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0245
Citation: ZHAO Lidan, MENG Xia, XU Haojie, ZHANG Fengchun. Prospect of Gut Microbiota Based Intervention in Autoimmune Disease Control[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0245

肠道菌群在自身免疫性疾病治疗中的前景

doi: 10.12290/xhyxzz.2022-0245
基金项目: 

国家自然科学基金( 82071840) ; 中国医学科学院医学与健康科技创新工程项目( CIFMS2020-I2M-C&T-B-013)

详细信息
    通讯作者:

    张奉春,E-mail:zhangfccra@aliyun.com

  • 中图分类号: R378;R593

Prospect of Gut Microbiota Based Intervention in Autoimmune Disease Control

Funds: 

National Natural Science Foundation of China (82071840), CAMS Innovation Fund for Medical Sciences (CIFMS 2020-I2M-C&T-B-013)

  • 摘要: 肠道菌群对于维持人体免疫稳态不可或缺。肠道菌群失调、易位及菌群代谢物异常见于多种自身免疫性疾病,通过诱导免疫失衡、分子模拟、旁观者激活、表位扩展等机制参与自身免疫耐受破坏和过度炎症反应,促进自身免疫性疾病的发生发展,并通过干扰药物在肠道的转化影响免疫治疗药物的疗效和毒性。基于肠道菌群的干预措施或可为自身免疫性疾病的防治提供新策略。本文回顾近年来肠道菌群在系统性自身免疫性疾病中的研究进展,并对基于菌群的干预措施在自身免疫性疾病中的应用前景予以展望。
  • [1] Hevia A, Milani C, Lopez P, et al. Intestinal dysbiosis associated with systemic lupus erythematosus[J]. mBio, 2014, 5:e01548-14.
    [2] He Z,Shao T, Li H, et al. Alterations of the gut microbiome in Chinese patients with systemic lupus erythematosus[J].Gut Pathog, 2016, 8:64.
    [3] Chen BD, Jia XM, Xu JY, et al. An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus[J]. Arthritis Rheumatol, 2021, 73:232-243.
    [4] Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to diseaseactivity associated expansions and immunity to a gut commensal[J]. Ann Rheum Dis, 2019, 78:947-956.
    [5] Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis[J]. Elife, 2013, 2:e01202.
    [6] Zhang X, Zhang D, Jia H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment[J]. Nat Med, 2015, 21:895-905.
    [7] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67:534-541.
    [8] Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis[J]. Ann Rheum Dis, 2017, 76:1614-1622.
    [9] Mandl T, Marsal J, Olsson P, et al. Severe intestinal dysbiosis is prevalent in primary Sjogren's syndrome and is associated with systemic disease activity[J]. Arthritis Res Ther, 2017, 19:237.
    [10] Cano-Ortiz A, Laborda-Illanes A, Plaza-Andrades I, et al. Connection between the Gut Microbiome, Systemic Inflammation, Gut Permeability and FOXP3 Expression in Patients with Primary Sjogren's Syndrome[J]. Int J Mol Sci, 2020, 21:8733.
    [11] Zhou C, Zhao H, Xiao XY, et al. Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis[J]. J Autoimmun, 2020, 107:102360.
    [12] Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis[J]. Ann Rheum Dis, 2017, 76:1614-1622.
    [13] Hall AB, Yassour M, Sauk J, et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients[J]. Genome Med, 2017, 9:103.
    [14] Gomez-Banuelos E, Mukherjee A, Darrah E, et al. Rheumatoid ArthritisAssociated Mechanisms of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans[J]. J Clin Med, 2019, 8:1309.
    [15] Bagavant H, Dunkleberger ML, Wolska N, et al. Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients[J]. Clin Exp Rheumatol, 2019, 37:106-111.
    [16] Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359:1156-1161.
    [17] Zegarra-Ruiz DF, El Beidaq A, Iniguez AJ, et al. A Diet-Sensitive Commensal Lactobacillus Strain Mediates TLR7-Dependent Systemic Autoimmunity[J]. Cell Host Microbe, 2019, 25:113-127. e6.
    [18] Ruff WE, Dehner C, Kim WJ, et al. Pathogenic Autoreactive T and B Cells CrossReact with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity[J]. Cell Host Microbe, 2019, 26:100-113. e8.
    [19] Greiling TM, Dehner C, Chen X, et al. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus[J]. Sci Transl Med, 2018, 10:eaan2306.
    [20] Szymula A, Rosenthal J, Szczerba BM, et al. T cell epitope mimicry between Sjogren's syndrome Antigen A (SSA)/Ro60 and oral, gut, skin and vaginal bacteria[J]. Clin Immunol, 2014, 152:1-9.
    [21] Zhang L, Zhang YJ, Chen J, et al. The association of HLA-B27 and Klebsiella pneumoniae in ankylosing spondylitis:A systematic review[J]. Microb Pathog, 2018, 117:49-54.
    [22] Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells[J]. Nature, 2013, 504:446-50.
    [23] Sivaprakasam S, Prasad PD, Singh N. Benefits of Short-chain fatty acids and their receptors in inflammation and carcinogenesis[J]. Pharmacol Ther, 2016, 164:144-151.
    [24] Rosser EC, Piper CJM, Matei DE, et al. Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells[J]. Cell Metab, 2020, 31:837-851,e10.
    [25] Sanchez HN, Moroney JB, Gan H, et al. B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids[J]. Nat Commun, 2020, 11:60.
    [26] Kidd BA, Ho PP, Sharpe O, et al. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination[J]. Arthritis Res Ther, 2008, 10:R119.
    [27] Bagavant H, Araszkiewicz AM, Ingram JK, et al. Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies[J]. Front Immunol, 2021, 12:635072.
    [28] Hsu TC, Huang CY, Liu CH, et al. Lactobacillus paracasei GMNL-32, Lactobacillus reuteri GMNL-89 and L. reuteri GMNL-263 ameliorate hepatic injuries in lupusprone mice[J]. Br J Nutr, 2017, 117:1066-1074.
    [29] Yeh YL, Lu MC, Tsai BC, et al. Heat-Killed Lactobacillus reuteri GMNL-263 Inhibits Systemic Lupus Erythematosus-Induced Cardiomyopathy in NZB/W F1 Mice[J]. Probiotics Antimicrob Proteins, 2021, 13:51-59.
    [30] Tzang BS, Liu CH, Hsu KC, et al. Effects of oral Lactobacillus administration on antioxidant activities and CD4+CD25+forkhead box P3(FoxP3)+T cells in NZB/W F1 mice[J]. Br J Nutr, 2017, 118:333-342.
    [31] Li Y, Wang HF, Li X, et al. Disordered intestinal microbes are associated with the activity of Systemic Lupus Erythematosus[J]. Clin Sci (Lond), 2019, 133:821-838.
    [32] Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359:91-97.
    [33] Artacho A, Isaac S, Nayak R, et al. The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis[J]. Arthritis Rheumatol, 2021, 73:931-942.
    [34] Nayak RR, Alexander M, Deshpande I, et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation[J]. Cell Host Microbe, 2021, 29:362-377,e11.
    [35] Zaragoza-Garcia O, Castro-Alarcon N, Perez-Rubio G, et al. DMARDs-Gut Microbiota Feedback:Implications in the Response to Therapy[J]. Biomolecules, 2020, 10:1479.
    [36] Araya RE, Goldszmid RS. Two Bugs a NOD Away from Improving Cancer Therapy Efficacy[J]. Immunity, 2016, 45:714-716.
    [37] Chen J, Wright K, Davis JM, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis[J]. Genome Med, 2016, 8:43.
    [38] Flannigan KL, Taylor MR, Pereira SK, et al. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil[J]. J Heart Lung Transplant, 2018, 37:1047-1059.
    [39] Taylor MR, Flannigan KL, Rahim H, et al. Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial betaglucuronidase activity[J]. Sci Adv, 2019, 5:eaax2358.
    [40] Kim DS, Park Y, Choi JW, et al. Lactobacillus acidophilus Supplementation Exerts a Synergistic Effect on Tacrolimus Efficacy by Modulating Th17/Treg Balance in Lupus-Prone Mice via the SIGNR3 Pathway[J]. Front Immunol, 2021, 12:696074.
    [41] Furukawa M, Moriya K, Nakayama J, et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis[J]. Hepatol Res, 2020, 50:840-852.
    [42] Bazin T, Hooks KB, Barnetche T, et al. Microbiota Composition May Predict AntiTnf Alpha Response in Spondyloarthritis Patients:an Exploratory Study[J]. Sci Rep, 2018, 8:5446.
    [43] Yin J, Sternes PR, Wang M, et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition[J]. Ann Rheum Dis, 2020, 79:132-140.
    [44] Zhou Y, Xu ZZ, He Y, et al. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction[J]. mSystems, 2018, 3 e00188-17.
    [45] Aden K, Rehman A, Waschina S, et al. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases[J]. Gastroenterology, 2019, 157:1279-1292. e11.
    [46] Pan H, Guo R, Ju Y, et al. A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis[J]. Microbiome, 2019, 7:107.
    [47] Zamani B, Golkar HR, Farshbaf S, et al. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis:a randomized, double-blind, placebo-controlled trial[J]. Int J Rheum Dis, 2016, 19:869-879.
    [48] Alpizar-Rodriguez D, Lesker TR, Gronow A, et al. Prevotella copri in individuals at risk for rheumatoid arthritis[J]. Ann Rheum Dis, 2019, 78:590-593.
    [49] Marietta EV, Murray JA, Luckey DH, et al. Suppression of Inflammatory Arthritis by Human Gut-Derived Prevotella histicola in Humanized Mice[J]. Arthritis Rheumatol, 2016, 68:2878-2888.
    [50] Mandel DR, Eichas K, Holmes J. Bacillus coagulans:a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial.[J] BMC Complement Altern Med, 2010, 10:1.
    [51] Shokryazdan P, Faseleh Jahromi M, Navidshad B, et al. Effects of prebiotics on immune system and cytokine expression[J]. Med Microbiol Immunol, 2017, 206:1-9.
    [52] Wilson B, Eyice O, Koumoutsos I, et al. Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis:Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms[J]. Nutrients, 2021, 13:3598.
    [53] Ho J, Nicolucci AC, Virtanen H, et al. Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes[J]. J Clin Endocrinol Metab, 2019, 104:4427-4440.
    [54] Moro G, Arslanoglu S, Stahl B, et al. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age[J]. Arch Dis Child, 2006, 91:814-819.
    [55] Zeng J, Peng L, Zheng W, et al. Fecal microbiota transplantation for rheumatoid arthritis:A case report[J]. Clin Case Rep, 2020, 9:906-909.
    [56] Kragsnaes MS, Kjeldsen J, Horn HC,et al. Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis:protocol for a 6-month, doubleblind, randomised, placebo-controlled trial[J]. BMJ Open, 2018, 8:e019231.
    [57] Picchianti Diamanti A, Panebianco C, Salerno G, et al. Impact of Mediterranean Diet on Disease Activity and Gut Microbiota Composition of Rheumatoid Arthritis Patients.[J] Microorganisms, 2020, 8:1989.
    [58] Gutierrez-Diaz I, Fernandez-Navarro T, Sanchez B, et al. Mediterranean diet and faecal microbiota:a transversal study[J]. Food Funct, 2016, 7:2347-2356.
    [59] Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal modulates TH17 axis and disease[J]. Nature, 2017, 551:585-589.
    [60] Zhang H, Liao X, Sparks JB, et al. Dynamics of gut microbiota in autoimmune lupus[J]. Appl Environ Microbiol, 2014, 80:7551-7560.
  • 加载中
计量
  • 文章访问数:  5
  • HTML全文浏览量:  0
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-02
  • 录用日期:  2022-07-15
  • 网络出版日期:  2022-07-28

目录

    /

    返回文章
    返回